Osteoporosis: An update

Bulletin of the NYU Hospital for Joint Diseases

Volumn 70, Issue 3, 2012, Pages 140-144

  Honig, Stephen ^a,b   Chang, Gregory ^c  

^a University School of Medicine   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

BONE DENSITY; BONE STRENGTH; CLINICAL FEATURE; COMPRESSION FRACTURE; COMPUTED TOMOGRAPHY SCANNER; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR FRACTURE; FEMUR SHAFT FRACTURE; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; INCIDENCE; LIFE EXPECTANCY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; SPINE FRACTURE;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIAGNOSTIC IMAGING; DIPHOSPHONATES; FEMORAL FRACTURES; HUMANS; LIFE EXPECTANCY; OSTEOPOROSIS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84869428876     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005 Mar;90(3):1294-301.
2. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures; report of a task force of the American Society for Mineral Research. J Bone Miner Res. 2010 Nov;25(11):2267-94.
3. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures; a register-based national cohort analysis. J Clin Endocrinol Metab. 2010 Dec;95(12):5258-65
4. Pazianas M, Abrahamsen B, Wang Y, Russell RG. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. Osteoporosis Int. 2012 Mar 20. [Epub ahead of print].
5. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphos-phonate use and risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011 Feb;305(8):783-9
6. Schilcher J, Michaelson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011 May 5;364(18):1728-37.
7. Meier RPH, Perneger TV, Stern R, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012 Jun 25;172(12):930-6.
8. Seeman E, Delmas PD. Bone quality-the material and structural bias of bone strength and fragility. N Engl J Med. 2006 May 25;354(21):2250-61.
9. Majumdar S. Magnetic resonance imaging of trabecular bone structure. Top Magn Reson Imaging. 2002 Oct;13(5):323-34.
10. Wehrli FW. Structural and functional assessment of trabecular and cortical bone by micro magnetic resonance imaging. J Magn Reson Imaging. 2007 Feb;25(2):390-409.
11. Stein EM, Liu XS, Nickolas TL, et al. Abnormal microarchitecture and reduced stiffness at the radius and tibia in postmenopausal women with fractures. J Bone Miner Res. 2010 Dec;25(12):2572-81.
12. Burghardt AJ, Kazakia GJ, Sode M, et al. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics and after turnover. J Bone Miner Res. 2010 Dec;25(12): 2558-71.
13. Rajapaske CS, Magland JF, Wald MJ, et al. Computational biomechanics of the distal tibia from high-resolutions MR and micro-CT images. Bone. 2010 Sep;47(3):556-63.
14. Kijowski R, Tuite M, Kruger D, et al. Evaluation of trabecular microarchitecture in nonosteoporotic postmenopausal women with and without fracture. J Bone Miner Res. 2012 Jul;27(7):1494-1500.
15. Cree MW, Juby AG, Carriere KC. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int. 2003 Sep;14(9):722-7.
16. Lyles KW, Colon-Emeric CS, Magaziner J, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 Nov 1;357(18):1799-809.
17. Colon-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. 2010 Jan;25(1):91-7
18. Bolland MJ, Grey AB, Gamble GD, Reid IR. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab. 2010 Mar;95(3):1174-81.
19. Center JR, Bliuc D, Nguyen N, et al. Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011 Apr;96(4):1006-14.
20. Bevilacqua M, Dominguez LJ, Rosini S, Bargagallo M. Bisphosphonates and atherosclerosis: why? Lupus. 2005;14(9):773-9.
21. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001 May;21(5):817-24.